- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
An AI Pulse Check
Three pieces of coverage in this month’s issue of Pharmaceutical Executive explore the tipping point that's seemingly on the cusp in artificial intelligence.
We are at an interesting crossroads in the advent of artificial intelligence (AI) and its application across a number of industries. This reality is perhaps none more apparent than in the biopharmaceutical and healthcare sectors.
Three pieces of coverage in
“AI will revolutionize the way we work, requiring us to learn new skills and undergo training to adapt to new processes and systems,” Abid Rahman, senior vice president of innovation at EVERSANA,
The question, however, as Hollan underscores, is will the perceived usefulness of these tools—and the many possibilities they have opened up already—ultimately catch on in the world of medicine? Or, perhaps more appropriately, is it time to really examine if they genuinely have caught on? And that’s coupled, of course, with the lingering concerns and debates around ethics and privacy that surround AI.
For his part, Rahman, in speaking with Hollan, points to several areas where he believes AI is making a tangible impact in pharma, including drug discovery and R&D, manufacturing and supply chain, marketing and commercialization, and even in drug pricing strategies. He also highlights, specifically, AI’s potential benefits for product launch and brand campaign tactics and decision-making.
Related to product launch as well, Natalie Harb, in a
Efforts of the sci-fi variety are expanding even more in healthcare, as columnist Bruce Liu, in a
Should all of this still be considered “hype” at this stage of the game? Are we in another bubble destined to burst? In trying to find the answers, the future is all about the now.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Articles in this issue
about 1 year ago
Pharmaceutical Executive: July/August 2024 Issue (PDF)about 1 year ago
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launchesabout 1 year ago
A Promising Option: Exxuaabout 1 year ago
Opening the Door: Omvohabout 1 year ago
'Marked’ for Stardom?: Truqapabout 1 year ago
Branching Off: Wegovyabout 1 year ago
A Formidable First: Winrevairabout 1 year ago
The Future of Launch Excellence is Generative AIabout 1 year ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'about 1 year ago
Big Bets, Bold StepsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.